Swiss vaccine developer Limma Tech get CARB-X grant
Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Curve Therapeutics raises £40.5m in Series A financing
/in News/by Thomas GabrielczykIntracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.
Pacifico Biolabs raises US$3.3m in pre-seed round
/in News/by Thomas GabrielczykGerman foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.<br /><br /><br /><br />
Gene therapy supplier MIP Discovery closes £7M Series A financing
/in News/by Thomas GabrielczykMIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.
Vidac Pharma Holding plc reports preclinical proof of principle
/in News/by Thomas GabrielczykLondon-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.
Roche leads Freenome Inc US$257m financing
/in News/by Thomas GabrielczykMulti-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection […]
Bioplastics production capacity to quadruple by 2028
/in News/by Thomas GabrielczykNew figures published by the industry association European Bioplastics suggest a sharp increase in the production of sustainable plastics in the next two years and calls for policy support.
AZmed closes €15m Series A financing
/in News/by Thomas GabrielczykParis-based AI-based medical imanging specialist AZmed SA has secured a €15min Series A financing led by Maison Worms, Techstars, and Tempact Ventures.
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
/in News/by Thomas GabrielczykBayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure.
German companies to revolutionise lab plastics market
/in News/by Thomas GabrielczykGerman Green Elephant Biotech has launched the world's first plant-based 96-well microtitre plate on the market.